Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle

Policy makers face challenges with the number of drugs for rare indications and rapidly rising costs. In facing these challenges, decision-makers see real-world evidence (RWE) as an opportunity. Health Canada and the Canadian Agency for Drugs and Technologies in Health (CADTH) recently announced the...

Full description

Saved in:
Bibliographic Details
Published in:Healthcare policy 2020-05, Vol.15 (4), p.41-47
Main Authors: Tadrous, Mina, Ahuja, Tarry, Ghosh, Basanti, Kropp, Rhonda
Format: Article
Language:English
Subjects:
Action
Decision makers
Decision making
Drugs
Life cycles
Policy making
Research Paper
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Policy makers face challenges with the number of drugs for rare indications and rapidly rising costs. In facing these challenges, decision-makers see real-world evidence (RWE) as an opportunity. Health Canada and the Canadian Agency for Drugs and Technologies in Health (CADTH) recently announced their intent to co-develop an action plan to optimize the process for the systematic use and integration of RWE into both regulatory and reimbursement decision-making in Canada. When implemented, this will have a significant impact on how drugs are approved and paid for in Canada. We highlight the key opportunities, barriers and future directions related to the use of RWE throughout the life cycle of drugs in Canada.
ISSN:1715-6572
1715-6580
DOI:10.12927/hcpol.2020.26225